Fraise A P, Brenwald N, Andrews J M, Wise R
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, UK.
J Antimicrob Chemother. 1995 Jun;35(6):877-81. doi: 10.1093/jac/35.6.877.
Two new glycylcyclines, CL 329,998 and CL 331,002, were tested for in-vitro activity against 178 clinical strains of enterococci which were resistant to one or more of the commonly used agents (ampicillin, high level gentamicin, vancomycin and teicoplanin). Both glycylcyclines demonstrated good activity (MICs < or = 0.5 mg/L) against all isolates tested, including those strains which demonstrated multiple resistance. As resistant enterococci are increasing in importance, new agents with activity against these strains are urgently required. Glycylcyclines have in-vitro activity which suggests they may be useful agents for treatment of infections caused by these organisms.
对两种新型甘氨酰环素CL 329,998和CL 331,002进行了体外活性测试，受试对象为178株对一种或多种常用药物（氨苄西林、高剂量庆大霉素、万古霉素和替考拉宁）耐药的肠球菌临床菌株。两种甘氨酰环素对所有受试分离株均表现出良好活性（最低抑菌浓度≤0.5mg/L），包括那些表现出多重耐药的菌株。由于耐药肠球菌的重要性日益增加，迫切需要具有抗这些菌株活性的新型药物。甘氨酰环素具有体外活性，这表明它们可能是治疗由这些微生物引起的感染的有用药物。
